Interpace Diagnostics Announces Appointment of New Director

World News: . []

PARSIPPANY, N.J., Sept. 13, 2017 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) (“Interpace” or “the Company”), a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services for improved patient diagnosis and management,  announced today that that Dr. Felice Schnoll-Sussman has been elected a director of the Company and a member of the Audit Committee.  Dr. Schnoll-Sussman will be a Class II director of the Company and her term will expire in 2018.  She will not be the subject of a stockholder vote at this year’s annual meeting of stockholders.

Dr. Schnoll-Sussman is Associate Professor of Clinical Medicine at Weill Medical College of Cornell University and is Associate Attending Physician in Gastroenterology at New York Presbyterian Hospital.  Dr. Schnoll-Sussman is the Director of the Jay Monahan Center for Gastrointestinal Health at Weill Cornell Medical College and has overall responsibility for all administrative, operational and financial aspects of the center.  She is a well-known expert on various esophageal, pancreatic and intestinal disorders, including Barrett’s Esophagus.  Dr. Schnoll-Sussman has her medical degree from the Mount Sinai School of Medicine and has also completed Executive Leadership Training at the Wharton School of Business.

The Company believes that with the appointment of Dr. Schnoll-Sussman to its Audit Committee, the Company will be in compliance with NASDAQ Listing Rule 5605(c)(2)(A), which requires that our Audit Committee be comprised of at least three members.

Jack E. Stover, President and CEO of Interpace Diagnostics, stated, “We are incredibly pleased that such a well-known expert in esophageal and gastrointestinal disorders has become a member of our board.  We look forward to her valuable contributions as Interpace continues to transform itself for growth.”

Interpace Diagnostics is a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services to evaluate the risk of cancer by leveraging the latest technology in personalized medicine for better patient diagnosis and management.  The Company currently has three commercialized molecular tests; PancraGEN for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; ThyGenX, for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay and ThyraMIR, for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay.  Interpace Diagnostics' mission is to provide personalized medicine through molecular diagnostics and innovation to advance patient care based on rigorous science.

CONTACT:Interpace Diagnostics Group, Inc.Investor Relations:Paul Kuntz – Redchip

More news and information about Interpace Diagnostics Group

Published By:

Globe Newswire: 13:30 GMT Wednesday 13th September 2017

Published: .

Search for other references to "interpace" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2017. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Ground Floor Offices, Little Keep Gate, Barrack Road, Dorchester, Dorset DT1 1AH
Registered in England and Wales number 0751938.
 
Privacy Policy | Terms and Conditions | Contact Us
 

Advertising on SPi News: Information For Advertisers